drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T)
drug_description
Autologous CD19-directed CAR T-cell therapy (Relma-cel) in which patient T cells are gene-modified to express an anti-CD19 chimeric antigen receptor, leading to activation and lysis of CD19+ B-lineage cells to deplete B cells and modulate autoimmunity.
nci_thesaurus_concept_id
C155878
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, relmacabtagene autoleucel target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_mesh_term
relmacabtagene autoleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express an anti-CD19 chimeric antigen receptor with costimulatory domains. After infusion, the CAR T cells recognize CD19 on B-lineage cells, activate, proliferate, secrete cytotoxic molecules and cytokines, and lyse CD19+ cells, leading to profound B-cell depletion (for malignant or autoreactive B-cell elimination).
drug_name
Relmacabtagene autoleucel
nct_id_drug_ref
NCT06414135